A new national guideline published in The Journal of Gastroenterology (2026) shows how the world’s liver societies are translating the MASLD era into clinic workflow. Japan’s evidence-based clinical practice guideline, its third revision, runs the full arc from definition to treatment, and its backbone decision is one this site has written about all month: the FIB-4 index becomes the first-line fibrosis screen for a disease most countries cannot scan their way through.
The logic is epidemiological arithmetic. MASLD is now the most prevalent chronic liver disease worldwide, and no health system can image everyone, so the guideline routes patients through noninvasive fibrosis assessment tools, with FIB-4, a formula combining age, AST, ALT, and platelet count, as the widely accessible first door and elastography as the second-line test for elevated scores.
The biopsy position is equally explicit and equally restrained. Liver biopsy is not routinely required for diagnosis, the guideline states, but remains essential for establishing at-risk MASH, assessing inflammatory activity, resolving discrepancies between noninvasive tests, and separating MASLD from other chronic liver disease, which is a surgical answer to a question most readers never knew had edges.
The definition section does quiet but consequential work. The guideline adopts the 2023 international consensus: steatotic liver disease with hepatic steatosis affecting at least 5 percent of hepatocytes plus at least one cardiometabolic risk factor, alcohol below 20 grams daily for women and 30 for men, and other causes excluded, and it carries the terminology’s intent, less stigma, more metabolism, into every algorithm that follows.
The prognosis architecture is the guideline’s sharpest claim. Advanced fibrosis is the major determinant of liver-related morbidity and mortality, which is why the entire screening apparatus exists: FIB-4 to find the risk, elastography to confirm it, specialist referral when the numbers say so, and the clinical questions in the document are all downstream of that one determinism.
The treatment hierarchy is where the guideline meets this site’s daily work. Lifestyle modification remains the foundation of management, the document states, with pharmacological therapy considered for patients with a high likelihood of at-risk MASH, which is the exact structure the site’s food pages assume: the plate is the base, the drugs are the layer above it, and neither replaces the other.
The comorbidity chapter reads like this month’s news feed. The guideline names MASLD’s associations with obesity, insulin resistance, dyslipidemia, and hypertension, and its elevated risks of cardiovascular disease, chronic kidney disease, and extrahepatic malignancy, which is the same map the CKD, statin, and frailty studies this month have been drawing cohort by cohort.
The FIB-4 accessibility point deserves a reader-facing note. The formula needs only age and three routine blood numbers, and a reader who has had a metabolic panel and a CBC already holds the ingredients, but the guideline’s structure is the caution too: an elevated score is the start of a structured workup with a clinician, never the end of one.
The alcohol boundary is drawn with clinical precision. Below 20 grams daily for women and 30 for men keeps a patient inside MASLD territory, above it the disease reclassifies as MetALD or alcohol-associated, and the guideline notes that liver injury can occur even at small amounts in some people, a nuance the binge-pattern study from earlier this week reinforced.
The burned-out MASLD concept is the guideline’s most quietly useful clinical pearl. In patients with cardiometabolic risk factors, late-stage disease can present with a scarred, quiet liver and little fat, and the guideline tells clinicians to consider that pattern and refer, which matters to readers with long-standing disease whose scans have grown deceptively calm.
The honest limits are the limits of all guidelines. GRADE-graded recommendations rest on the evidence available, much of it observational, practice patterns vary, and a Japanese document will not transfer byte-for-byte to US clinic workflows, but the FIB-4-first architecture it formalizes is the same direction American and European guidance has been walking.
For a reader, the practical translation is knowing the front door. If a clinician orders a FIB-4, that is the system working as designed, cheap and accessible first, imaging second, biopsy rarely, and the reader’s job in that system is the part no guideline can prescribe: the friendly plate, the movement, and the weight trend that determine where in the algorithm the years will land.
None of this replaces the clinician. Screening intervals, elastography referrals, biopsy decisions, and pharmacotherapy choices are all clinician territory under this very document, and the reader who wants a number should ask for one at a visit rather than computing a score into a self-verdict.
For a reader, the takeaway is that the bureaucracy of fatty liver care has settled into a shape: one cheap formula at the front door, one scan behind it, one tissue test reserved, and lifestyle as the floor under all of it, which is the clearest official confirmation yet of the position this site has held since its first page.
The international echo closes the thought. Japan’s third revision joins the AASLD, EASL, and EASO documents this site has covered, and across all of them the constellation repeats: FIB-4 screening, noninvasive-first diagnostics, lifestyle foundation, drugs for at-risk MASH, which means the reader asking what the standard of care is can hear one answer in four accents.
The patient-communication section is the part of the guideline a reader can feel directly. Documents like this define what a first visit should include, which questions the clinic will ask, which numbers it will compute, and which lifestyle advice is now standard of care rather than personal enthusiasm, so the reader walking in with MASLD or its risk factors is walking into a system that has, on paper at least, already agreed with the food-first position.
What are the guideline’s key recommendations?
The 2026 Japanese guideline makes the FIB-4 index the widely accessible first-line fibrosis screen, reserves elastography for elevated FIB-4 or suspicious cases, keeps liver biopsy for at-risk MASH confirmation and discrepancies, and holds lifestyle modification as the foundation of management with pharmacotherapy for high-likelihood at-risk MASH.
What is FIB-4 and can readers compute it?
FIB-4 combines age, AST, ALT, and platelet count into one number. The formula is public, but interpretation and follow-up testing belong to a clinician, because a single elevated score triggers a structured second-line workup rather than a self-diagnosis.
What does this mean for diet?
The guideline keeps lifestyle modification as the foundation on which any drug sits, which is the same position this site occupies: the friendly plate, weight management, and exercise are the base layer every treatment algorithm assumes.